# 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

> **NCT05673031** · — · RECRUITING · sponsor: **Alberta Health services** · enrollment: 500 (estimated)

## Conditions studied

- Neuroendocrine Tumors (NET)

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-HA-DOTATATE PET/CT imaging

## Key facts

- **NCT ID:** NCT05673031
- **Lead sponsor:** Alberta Health services
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673031, "68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05673031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*